Newspaper publication of Standalone Audit Financial Results for Fourth Quarter and Financial Year ended on 31st March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shukra Pharmaceuticals has published its audited financial results for Q4 FY26 and full year FY26 in Business Standard and Jai Hind newspapers. The standalone results show total income from operations of Rs 725.01 lakhs for Q4 and Rs 14,735.1 lakhs for FY26. The company reported profit before tax of Rs 367.5 lakhs (Q4) and Rs 757.01 lakhs (FY26), with profit after tax of Rs 172.67 lakhs and Rs 538.64 lakhs respectively. Basic EPS stands at 0.04 for Q4 and 0.42 for full year. The consolidated results are largely similar, with Q4 PAT at Rs 71.62 lakhs and FY26 PAT at Rs 538.64 lakhs. The results were reviewed by the Audit Committee and approved by the Board of Directors on May 7, 2026.
The company has reported a net profit of Rs 5.39 crore for FY26, showing significant improvement from FY25's profit of Rs 57.51 lakhs. This strong profit growth may be viewed positively by investors, though the company remains relatively small with a market cap likely under Rs 50 crore.